Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06288659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial

Study acronym: ASTIM
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Huashan Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 5 more changesShow less
    • Interventions modified
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints revised (6)
    • Study description shortened, about 6 words
    • Publications: 8 to 10
  2. Start date: May 20, 2024 to Jul 19, 2024v9 Show 6 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jun 30, 2026 to Jul 29, 2026
    • Study completion date: Dec 30, 2026 to Oct 30, 2026
    • Eligibility criteria shortened, about 19 words
    • Secondary endpoints revised (6)
    • Site details revised
  3. Enrollment target: 368 to 372
    • Eligibility criteria expanded, about 5 words
    v8
  4. Eligibility criteria shortened, about 43 wordsv7
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2024 to May 20, 2024
    • Site details revised
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date: Apr 1, 2024 to May 1, 2024
    • Interventions: Intracranial pressure monitoring (Device) to Intraventricular intracranial pressure monitoring (Device)
    • Study description expanded, about 1 word
    • Study title expanded, about 5 words
    v5
  2. Eligibility criteria expanded, about 2 wordsv4
  3. Re-verified, no change to tracked fieldsv3
  4. Start date: Feb 25, 2024 to Apr 1, 2024
    • Eligibility criteria shortened, about 7 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Huashan Hospital
96 trials monitored
See 4 trials at risk
Hypertension
1,925 trials monitored
See 99 trials at risk
ASTIM is a multicenter, prospective, randomised, blinded end-point assessed trial, to investigate the efficacy and safety of treatment based on intracranial pressure monitoring in improving the prognosis of patients with aneurysmal subarachnoid hemorrhage.
Trial Details
NCT Number NCT06288659
Lead Sponsor Huashan Hospital
Conditions
(from sponsor)		 Aneurysmal Subarachnoid Hemorrhage, Intacranial Hypertension
Related terms Subarachnoid Hemorrhage
Enrollment 372 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov